Leigh Ellis, PhD, and colleagues at Roswell Park Comprehensive Cancer Center (Roswell Park) have identified two genes that appear to be simultaneously overexpressed in
aggressive prostate cancers resistant to the androgen - targeted treatments enzalutamide and abiraterone acetate.
His laboratory is interested in understanding the role of metabolic adaptations in breast and
prostate cancer progression, and elucidating mechanisms that promote therapy
resistant aggressive metastatic disease.